Literature DB >> 24799327

Reply: To PMID 24677197.

Bryan C Fuchs1, Yujin Hoshida, Kenneth K Tanabe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24799327      PMCID： PMC4221577          DOI： 10.1002/hep.27208

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  8 in total

Review 1.  Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.

Authors:  Liang Shi; Junfang Tang; Li Tong; Zhe Liu
Journal:  Lung Cancer       Date:  2013-11-27       Impact factor: 5.705

2.  Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Cristine Allmer; James Thomas; Henry C Pitot; George Kim; Ross C Donehower; Tom Fitch; Joel Picus; Charles Erlichman
Journal:  J Clin Oncol       Date:  2005-09-20       Impact factor: 44.544

3.  Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma.

Authors:  Bryan C Fuchs; Yujin Hoshida; Tsutomu Fujii; Lan Wei; Suguru Yamada; Gregory Y Lauwers; Christopher M McGinn; Danielle K DePeralta; Xintong Chen; Toshihiko Kuroda; Michael Lanuti; Anthony D Schmitt; Supriya Gupta; Andrew Crenshaw; Robert Onofrio; Bradley Taylor; Wendy Winckler; Nabeel Bardeesy; Peter Caravan; Todd R Golub; Kenneth K Tanabe
Journal:  Hepatology       Date:  2014-02-28       Impact factor: 17.425

4.  Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma.

Authors:  Min-Cheng Su; Huang-Chun Lien; Yung-Ming Jeng
Journal:  Cancer Lett       Date:  2005-06-16       Impact factor: 8.679

5.  Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.

Authors:  Bryan C Fuchs; Tsutomu Fujii; Jon D Dorfman; Jonathan M Goodwin; Andrew X Zhu; Michael Lanuti; Kenneth K Tanabe
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

6.  Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.

Authors:  Melanie B Thomas; Romil Chadha; Katrina Glover; Xuemei Wang; Jeffrey Morris; Thomas Brown; Asif Rashid; Janet Dancey; James L Abbruzzese
Journal:  Cancer       Date:  2007-09-01       Impact factor: 6.860

7.  Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: a novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma.

Authors:  Irene Centeno; Pilar Blay; Iñigo Santamaría; Aurora Astudillo; Ana S Pitiot; Fernando G Osorio; Patricia González-Arriaga; Fernando Iglesias; Primitiva Menéndez; Adonina Tardón; Jose M Freije; Milagros Balbín
Journal:  BMC Cancer       Date:  2011-05-16       Impact factor: 4.430

8.  Acute Fatal Liver Toxicity under Erlotinib.

Authors:  Sabina Schacher-Kaufmann; Miklos Pless
Journal:  Case Rep Oncol       Date:  2010-06-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.